Forrestin A is primarily used in research settings for its potential anti-cancer properties. It functions as a multi-kinase inhibitor, targeting key signaling pathways involved in tumor growth and angiogenesis. Due to its ability to inhibit receptors such as c-Met and VEGFR2, it has shown promise in preclinical studies for suppressing the progression of certain solid tumors. Its application extends to studies on drug resistance mechanisms and combination therapies with other oncology agents. Currently, it remains an investigational compound and is not approved for clinical use, but it serves as a valuable tool in oncology and pharmacology research.